Loading
Chaired the SIOPEN HR-NBL1 trial, the largest neuroblastoma trial ever, which set European standards for high-risk disease.
Ruth Ladenstein (Vienna) chaired SIOPEN HR-NBL1, the 3,000-patient trial that established busulfan-melphalan as the preferred myeloablative regimen for high-risk neuroblastoma and showed that adding interleukin-2 to dinutuximab beta immunotherapy adds toxicity without benefit. She has led SIOP Europe and coordinates the European neuroblastoma research network.
Shares Neuroblastoma (paediatric) and the tags paediatric, cooperative-group.
Shares Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
Shares Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
Shares Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
Shares SIOPEN HR-NBL1, Neuroblastoma (paediatric) and the tag cooperative-group.
Shares SIOPEN HR-NBL1, Neuroblastoma (paediatric).
Shares the tags paediatric, cooperative-group.
Shares the tags paediatric, cooperative-group.